These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 30180826)

  • 1. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
    BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
    Yeowell G; Smith P; Nazir J; Hakimi Z; Siddiqui E; Fatoye F
    BMJ Open; 2018 Nov; 8(11):e021889. PubMed ID: 30467131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overactive bladder medication: Persistence, drug switching, and reinitiation.
    Soda T; Tashiro Y; Koike S; Ikeuchi R; Okada T
    Neurourol Urodyn; 2020 Nov; 39(8):2527-2534. PubMed ID: 32985716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirabegron has longer treatment persistence than antimuscarinics: Real-world data from a Korean national cohort database.
    Lee KS; Park H; Kang D; Byun HJ; Foo CY; Hadi FA; Kim S; Cho J
    Neurourol Urodyn; 2021 Nov; 40(8):1972-1980. PubMed ID: 34486168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
    Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
    Kato D; Uno S; Van Schyndle J; Fan A; Kimura T
    Int J Urol; 2017 Oct; 24(10):757-764. PubMed ID: 28833621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
    Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
    PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence with mirabegron in a real-world clinical setting.
    Wada N; Watanabe M; Banjo H; Tsuchida M; Hori J; Tamaki G; Azumi M; Kita M; Kakizaki H
    Int J Urol; 2018 May; 25(5):501-506. PubMed ID: 29651798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ; Cho ST; Kuo HC; Chou EC; Hsu YC; Lee KS; Hadi F; Song Y; Sumarsono B
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
    Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
    Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.